When extended to primary CLL lymphocytes, this inhibitory activity was confirmed in CLL cells harboring BTKWT or mutant BTK during in vitro investigation (Fig. 3). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.